Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,648,015 papers from all fields of science
Search
Sign In
Create Free Account
certolizumab pegol
Known as:
CERTOLIZUMAB
, Certolizumab Pegol [Chemical/Ingredient]
, Pegol, Certolizumab
Expand
A Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
15 relations
1 ML certolizumab pegol 200 MG/ML Prefilled Syringe
1 ML certolizumab pegol 200 MG/ML Prefilled Syringe [Cimzia]
In Blood
agonists
Expand
Broader (2)
Antirheumatic Agents
Immunosuppressive Agents
Narrower (2)
CDP870
Cimzia
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abicipar pegol—a novel anti-VEGF therapy with a long duration of action
E. Moisseiev
,
A. Loewenstein
Eye
2019
Corpus ID: 202688419
Intravitreal injections have revolutionized the management of retinal diseases, and since their advent have rapidly become the…
Expand
2014
2014
1 Achievement of Developmental Milestones Among Offspring of Women With Inflammatory Bowel Disease: The PIANO Registry
U. Mahadevan
,
Christopher F. Martin
,
+4 authors
B. Sands
2014
Corpus ID: 71989087
Review
2012
Review
2012
Biologic Therapies for Spondyloarthritis: What Is New?
X. Baraliakos
,
J. Braun
Current Rheumatology Reports
2012
Corpus ID: 24846930
The course of axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS), is strongly influenced by the degree of…
Expand
2011
2011
A gallogermanate zeolite constructed exclusively by three-ring building units.
Yide Han
,
Yi Li
,
Jihong Yu
,
Da Xu
Angewandte Chemie
2011
Corpus ID: 8524380
Zeolites have microporous structures constructed by tetrahedrally connected atoms (T atoms, e.g., Si, Al, P, and Ge) and have…
Expand
Highly Cited
2010
Highly Cited
2010
Mucosal healing and anti TNFs in IBD.
G. Van Assche
,
S. Vermeire
,
P. Rutgeerts
Current Drug Targets
2010
Corpus ID: 43492006
Mucosal healing has been incorporated in the assessment of treatment efficacy in ulcerative colitis, but in Crohn's disease this…
Expand
Review
2010
Review
2010
Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
Thomas W. Lee
,
R. Fedorak
Gastroenterology Clinics of North America
2010
Corpus ID: 7339503
2010
2010
Psoriatic skin lesions induced by certolizumab pegol.
R. Klein
,
J. Spivack
,
K. Choate
Archives of Dermatology
2010
Corpus ID: 23628639
dysesthesia but showed no skin eruption. Neuropathic pain might lead to sympathetic hyperactivity or decreased muscular activity…
Expand
Review
2009
Review
2009
Clinically Meaningful Improvement in Health-Related Quality of Life in a Randomized Controlled Trial of Certolizumab Pegol Maintenance Therapy for Crohn's Disease
B. Feagan
,
G. Coteur
,
S. Tan
,
D. Keininger
,
S. Schreiber
American Journal of Gastroenterology
2009
Corpus ID: 37596384
OBJECTIVES:Moderate-to-severe Crohn's disease (CD) is associated with important impairment in health-related quality of life…
Expand
2007
2007
Current and future anti-TNF therapy for inflammatory bowel disease
M. Osterman
,
G. Lichtenstein
Current treatment options in gastroenterology
2007
Corpus ID: 9509653
Opinion statementAnti-tumor necrosis factor-α (anti-TNF) therapy has become a very important modality in the treatment of…
Expand
2001
2001
NaZn(H2O)2[BP2O8].H2O: a novel open-framework borophosphate and its reversible dehydration to microporous sodium zincoborophosphate N.
I. Boy
,
F. Stowasser
,
G. Schäfer
,
Rüdiger Kniep
Chemistry
2001
Corpus ID: 45346076
Crystals of NaZn(H2O)2[BP2O8].H2O were grown under mild hydrothermal conditions at 170 degrees C. The crystal structure (solved…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE